Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | VDR | P11473 | 5/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23923488 | 1.00 | HTR2A (0.42) | HTR2AHTR2CHTR2BCA12CA1 | |
| SCHEMBL1662282 | 0.81 | HTR2C (0.46) | HTR2CCA12CA1CA9HSP90AA1 | |
| SCHEMBL7706827 | 0.78 | CA1 (0.50) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL3093088 | 0.75 | HSP90AA1 (0.38) | HTR2AHTR2CHTR2BCA12CA1 | |
| SCHEMBL8333649 | 0.75 | HTR2C (0.63) | HTR2AHTR2CHTR2BCA1CA9 | |
| SCHEMBL28991665 | 0.74 | HTR2C (0.45) | HTR2AHTR2CHTR2BSLC9A1CHRM2 | |
| Ammonia Solution, Strong SCHEMBL267089 | 0.74 | HTR2C (0.61) | HTR2AHTR2CHTR2BCA1CA9 | |
| SCHEMBL28991666 | 0.74 | HTR2C (0.45) | HTR2AHTR2CHTR2BSLC9A1CHRM2 | |
| SCHEMBL3182564 | 0.73 | CA12 (0.46) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL23993603 | 0.73 | TAS1R3 (0.44) | HTR2AHTR2CHTR2BSLC9A1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010912-A | Antiviral 1, 3-dioxoindene compounds | 诺华股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250188066-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-06-12 | — | — | US | disclosed |
| US-12286423-B2 | Antiviral 1,3-di-oxo-indene compounds | NOVARTIS AG (CH) | 2025-04-29 | — | — | US | disclosed |
| CN-115867545-A | Antiviral 1,3 dioxoindene compounds | 诺华股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-4139301-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | Novartis AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021214080-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| US-20210323947-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188066-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, ZC3HAV1 | HTR2A 4358/4885HTR2C 3191/4885HTR2B 4195/4885 |
| US-20210323947-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, ZC3HAV1 | HTR2A 4358/4885HTR2C 3191/4885HTR2B 4195/4885 |
| US-12286423-B2 | Antiviral 1,3-di-oxo-indene compounds | IRF3, EIF2AK2, ZC3HAV1 | HTR2A 4358/4885HTR2C 3191/4885HTR2B 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.